Real-World study tracks immune response in lung cancer patients after standard treatment
NCT ID NCT06634199
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This observational study follows 50 people with stage III non-small cell lung cancer who have already received chemo-radiotherapy and are about to start immunotherapy with durvalumab. Researchers will look at how the immune system responds and whether that relates to survival. The goal is to learn more about real-world outcomes, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab (Imfinzi)
- What this could lead to
- If successful, this study could help doctors understand which patients benefit most from immunotherapy after chemo-radiotherapy for stage III lung cancer.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not apply to all patients due to the small size and real-world variability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Complejo Hospitalario Universitario Del Ferrol
RECRUITINGFerrol, A Coruña, 15405, Spain
-
Complexo Hospitalario Universitario De Vigo
RECRUITINGVigo, Vigo, 36204, Spain
-
Hospital Clínico San Carlos
RECRUITINGMadrid, Madrid, 28040, Spain
-
Hospital Clínico Universitario de Valladolid
RECRUITINGValladolid, Valladolid, 47003, Spain
-
Hospital De Basurto
RECRUITINGBilbao, Bilbao, 48013, Spain
-
Hospital General Universitario de Alicante
RECRUITINGAlicante, Alicante, 03010, Spain
-
Hospital General Universitario de Ciudad Real
RECRUITINGCiudad Real, Ciudad Real, 13005, Spain
-
Hospital Universitari Vall d' Hebron
RECRUITINGBarcelona, Barcelona, 08035, Spain
-
Hospital Universitari de Gran Canària Doctor Negrín
RECRUITINGLas Palmas de Gran Canaria, Las Palmas, 35010, Spain
-
Hospital Universitario Central De Asturias
RECRUITINGOviedo, Oviedo, 33011, Spain
-
Hospital Universitario De La Princesa
RECRUITINGMadrid, Madrid, 28006, Spain
-
Hospital Universitario Fundación Jiménez Díaz
RECRUITINGMadrid, Madrid, 28040, Spain
-
Hospital Universitario La Paz
RECRUITINGMadrid, Madrid, 28046, Spain
-
Hospital Universitario Lucus Augusti
RECRUITINGLugo, Lugo, 27003, Spain
-
Hospital Universitario Nuestra Señora de Candelaria
RECRUITINGSanta Cruz de Tenerife, Santa Cruz de Tenerife, 38010, Spain
-
Hospital Universitario Puerta de Hierro
RECRUITINGMajadahonda, Madrid, 28222, Spain
-
Hospital Universitario Y Politécnico La Fe
RECRUITINGValencia, Valencia, 46026, Spain
-
Hospital Virgen del Rocio
RECRUITINGSeville, Sevilla, 41013, Spain
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, Barcelona, 08041, Spain
-
Hospitalario Universitario A Coruña
RECRUITINGA Coruña, La Coruña, 15006, Spain
-
ICO Badalona, Hospital Germans Trias i Pujol
RECRUITINGBadalona, Barcelona, 08916, Spain
-
ICO Girona, Hospital Josep Trueta
RECRUITINGGirona, Girona, 17007, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to keep lung cancer at bay
- Step counts may predict trouble during lung cancer therapy
- New pill targets Hard-to-Treat lung cancer in patients who Can't have standard therapy
- New drug cocktail aims to shrink inoperable lung tumors enough for surgery
- New combo therapy aims to stop lung cancer from returning
- Radioactive 'Smart Bomb' targets cancer in new human trial